Michael Ryskin
Stock Analyst at B of A Securities
(1.40)
# 3,423
Out of 4,944 analysts
37
Total ratings
47.83%
Success rate
-2.97%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $68 → $70 | $69.63 | +0.53% | 6 | Jun 25, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $535 → $475 | $663.92 | -28.46% | 3 | Apr 21, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Buy | $9 → $8 | $2.75 | +190.91% | 3 | Mar 3, 2025 | |
| ALGN Align Technology | Maintains: Underperform | $200 → $206 | $145.74 | +41.35% | 6 | Dec 13, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $58.57 | -31.71% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $3.88 | +144.85% | 1 | Jun 25, 2024 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $11.17 | +114.86% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $13.07 | +83.63% | 2 | Jul 31, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $152.44 | +18.08% | 7 | Nov 4, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $5.70 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $19.84 | +162.10% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $3.12 | +220.51% | 2 | Nov 10, 2021 |
Tempus AI
Jun 25, 2025
Maintains: Neutral
Price Target: $68 → $70
Current: $69.63
Upside: +0.53%
IDEXX Laboratories
Apr 21, 2025
Maintains: Neutral
Price Target: $535 → $475
Current: $663.92
Upside: -28.46%
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.75
Upside: +190.91%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200 → $206
Current: $145.74
Upside: +41.35%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $58.57
Upside: -31.71%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $3.88
Upside: +144.85%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $11.17
Upside: +114.86%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $13.07
Upside: +83.63%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $152.44
Upside: +18.08%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.70
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $19.84
Upside: +162.10%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $3.12
Upside: +220.51%